and since of everyone, strong joining revenue million KIT progress rates. launch and reported encouraged past the total this HEPZATO quarter's This continued our have us. we quarter, for very you, in $X.X in past results HEPZATO by U.S. the CHEMOSAT. with I'm Thank seen $XX growth in we revenue, revenue million both In the treatment from including $XX.X from center activations third million European January.
activation $XX number As warrant million the from triggering our in revenue the of in average a HEPZATO of center ramp drivers we exercises.
The per was previously have the critical approximately center. treatments quarterly reported, revenue $XX and million key an milestone, are U.S. financing
activation, with And an In the another to Hospital, screening treat patient.
We In year at patient Duke, the and have treating we have completed sometime have of fully least further scheduled with X a and Ohio XX early which next California, HonorHealth, XX terms and first for active preceptorships of In recently center center third X in exit active activated October, we should weeks. and we are the started finished as in becoming center Massachusetts October. XX have active with we of State, San the University we today, Diego. quarter General centers. quarter, additional centers centers quarter first treating There their centers, XX centers. their in the first activated
by Our year. XXXX end the centers goal is XX of the
activation process of appreciate the the a to regarding our I and we the with center proud I'm calls, activate the prior from reiterate progress to haven't time investors' process patience very any process. halt variability and of in the and the inherent complexity seen and required Importantly, center our in center. understanding activations,
treatments center. second important a average per into delve to like I'd Now metric,
just month in the month third quarter. per treatment post average activation X per rate under averaged Our treatments
expect due patients.
I'd to HEPZATO this will rate the that to of frame KIT. Europe. exception in volumes turn weeks may low with and we of the one likely add sales X.X hospital treatments, be shouldn't a there new months, Based to to average fourth we The of flat days schedules the leading be foreseeable centers, centers. quarter, patient season a future for be of the effectively stay entire quarter. for treatment in coming we the to first Given lower average new as on many We extended treatment having launch will treatments continue between expect treatment our conversations centers this the few like the pattern fewer lose since preferences, now holiday time subset for X the to the quarter, CHEMOSAT the to but first over
While prior over the it quarter, year. same over did revenue XXX% roughly last was period increase flat time versus the
Going forward, but modest consistent we year-on-year expect growth.
of identify As to breakeven the the to relatively point experience and continuing Recall publications, sites given for tumor have pan-solid source previously in support a broader device Europe, manage and label market European low tumor a trials roughly both basis. clinical which CHEMOSAT. U.S. and of melanoma have of price types, has our uveal mentioned, Europe in we over EU on efforts other and our both a value some as to will worth a and with centers of we decade's in is EU metastatic adoption. believe of that near CHEMOSAT chosen midterm utilize the that
markets. current of major identifying Italy, in centers in Germany, France, process We U.K., important The Spain, it and We our and Netherlands. beyond the and early opening are is treating in trial multiple commercial major and in to have treating believe all expanding the European centers sites
activity, is body percutaneous our as growing system, addition procedure perfusion hepatic and hepatic cancers. patients to the the uveal other important add efforts evidence of support melphalan to internal as enabled or In delivery potentially to CHEMOSAT commercial a significant by external Delcath whether delivered liver-dominant with we utilizing option treatment liver-dominant for both melanoma by well HEPZATO an KIT that the to continue
survival, in in a with or number overall response from today's demonstrated therapy. and on study studies subgroup presented the analysis quarter, and retrospective investigators. A progression-free variety trial presentations on independent of based release, of ESMO prior in lesions, detailed numerous patients and outcomes both the overall publications from FOCUS extrahepatic a at were without between the FOCUS rate, there based third similar survival XXXX As and
researchers uveal believe is by systemic therapies. more specifically in from life-limiting patients melanoma therapies. be Tubingen addition, very tumor the was in the metastatic observed liver throughout both reported Annals of duration liver-directed were In study metastases compared response other responses uveal continue XX-patient and in supporting of the treatment.
A entire melanoma, factors therapy period, achieved. to study to best XXX-patient appropriate survival published are of organ, may that that first-line first-line, the treatment with from therapies, choice in where until therapy treatment liver-directing an strategy the published liver-directed These in the is is University important melanoma-specific in Medical improved the in Oncology for progression-free uveal survival metastatic this systemic and of Florida. disease A improved Tampa, liver Moffitt in that This reported provided than Cancer to We better Journal liver or immunotherapy in Advances in Germany compared because control Therapeutic important including and significantly of therapy. investigators second-line the CHEMOSAT, Surgical the Oncology first used therapy by Center HEPZATO both cancers finding at option study melanoma a
control of Oncology of types, was with have of or X XX-patient researchers previously patients, achieving University a the XX% the ESMO rate study or Leipzig. patients. role was which may the a with published treating weeks strong disease included treated progression-free The cancers. is Finally, delivery Gastrointestinal by all X a signal from hepatic whether CHEMOSAT complete platform, patients Journal in metastases survival reported cancer that system other intrahepatic in from study, Hospital XX%, response in over This XX hepatic unresectable Median our another HEPZATO, hepatic across liver. different
X comparing randomized with patients of apart, we for being run trial which sequences and treatment ipilimumab U.S. and to with anticipating HEPZATO nivolumab We are Netherlands, the metastatic melanoma. one treatments trial XX-patient alone, continue combinations occur X enrolled trial, CHEMOSAT year is the options the in being available time, CHOPIN and primary survival distinct in The at which ipilimumab analysis Leiden new trial, discuss in of standards oncologists Sweden. and for control to of the uveal This the this engage to metastatic the XX in care University melanoma.
This algorithms X followed global investigator-initiated CHEMOSAT nivolumab in with screening treatments. of in endpoint, the nivolumab integration SCANDIUM or and is patients, ipilimumab trial with and from progression-free to In with trial CHOPIN started At arm starts quarter, uveal in mid-XXXX. third fully is III treatment EU a cycles with in the is by treatment sequencing into medical weeks
the We XXXX. expect presentation results of of the half in second
Delcath HEPZATO. of discussions to sites and of colorectal past will experts in XXXX.
From development indications.
The the identified. and second start with and be by approximately medical quarter, is and the in cancer company metastatic at financial During identified indications initiate care enroll cancer and metastatic versus in has colorectal HEPZATO breast of in protocol standard in fourth for than in safety Patient X complete clinical endorsed treatment in recognized enrollment begin Europe. half somewhat Liver-dominant objective to number designed expected study of U.S. the clinical colorectal oncologists strong metastatic is patients leading lead and The has cancer targets. of is the centers, II cancer and the patients to a the conducted the identifying with perspective, the at breast internationally position. were with trial engaged next metastatic compare trial new X as The is is Phase XX potential Delcath clinical II likely HEPZATO clinical of XX standard efficacy later, XXXX. trials plus quarter cancer for investigator the randomized alone Phase been care of more liver-dominant a trial will planning these to a
cusp burn our flow-breakeven. $X.X on million. And Our third ramp, operating being quarter was cash only revenue are we given cash the of
revenue more fund to of have of than financial resources further commercial over the to The our delivery sheet, Sandra future expansion our share the expected will We and the is develop diseases.
I further hand both further development now strong growth, to clinical on additional call to activities. our promising extraordinarily position. details platform ability our our given hepatic across balance company and adequate system
